Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

De Sanctis, R; Bruzzi, P; Zambelli, A

Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

De Sanctis, R; Bruzzi, P; Zambelli, A.

Afiliación

De Sanctis R; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan. Electronic address: rita.de_sanctis@hunimed.eu.
Bruzzi P; Department of Health Sciences, University of Genoa, Genova, Italy.
Zambelli A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan.

Ann Oncol ; 2024 Sep 03.

Article en En | MEDLINE | ID: mdl-39236982

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google